Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00331981 |
Primary purpose:
Secondary purpose:
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Amisulpride |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Study of the Efficacy and Safety After Long-Term Treatment With Amisulpride in Schizophrenic Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | L_8968 |
Study First Received: | May 30, 2006 |
Last Updated: | April 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00331981 |
Health Authority: | South Korea: Korea Food and Drug Administration (KFDA) |
Schizophrenia Dopamine Mental Disorders |
Sultopride Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Dopamine Agents Dopamine Antagonists Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions |